Marc Mayhew, MD
Interventional Cardiology · Kingsport, TNNPI 1710098546
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,918 of the $8,281 with a category attached, or 83.5%. 28 manufacturers reported payments, led by Abbott at 35.0% of the total. Reporting peaked in 2023 at $2,828 and has fallen 55.6% since, to $1,255 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TN, where the typical reported total is $7,646.
Across 340 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Abiomed$1K
- Boston Scientific$796
- E.r. Squibb & Sons, L.L.C.$578
- Novartis$485
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$445
- plus $2K from 22 others
Across 19 payments — averaging $1424.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$27K
What the payments were for
- Travel & lodging$1,36316%
- Food & beverage$6,91884%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 89 | $2,898 |
| Abiomed | 24 | $1,219 |
| Boston Scientific | 34 | $796 |
| E.r. Squibb & Sons, L.L.C. | 40 | $578 |
| Novartis | 28 | $485 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 28 | $445 |
| Johnson & Johnson | 17 | $253 |
| Angiodynamics, Inc. | 8 | $213 |
| AstraZeneca | 15 | $199 |
| Pfizer | 11 | $181 |
| Edwards Lifesciences | 5 | $129 |
| Inari Medical, Inc. | 7 | $117 |
| Philips North America LLC | 5 | $110 |
| Atricure, Inc. | 2 | $93 |
| Shockwave Medical, Inc | 2 | $84 |
| Boehringer Ingelheim | 5 | $82 |
| Cardiovascular Systems Inc. | 6 | $77 |
| Amgen | 3 | $67 |
| Heartflow, Inc. | 1 | $50 |
| Teleflex LLC | 1 | $34 |
| Medtronic(2 entities) | 2 | $33 |
| Stryker | 1 | $29 |
| Lemaitre Vascular, Inc. | 1 | $29 |
| Biosense Webster, Inc. | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER TALISMAN$1,391
- Impella$407
How this compares
$8,281 in reported general payments places this provider in the 50th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 378 | $295,732 |
| EntrestoSacubitril/Valsartan | 57 | $53,139 |
| XareltoRivaroxaban | 46 | $41,110 |
| BrilintaTicagrelor | 47 | $27,154 |
| Ranolazine ErRanolazine | 92 | $11,060 |
| FarxigaDapagliflozin Propanediol | 17 | $9,863 |
| Prasugrel Hcl | 64 | $7,971 |
| Metoprolol Succinate | 257 | $3,026 |
| ClopidogrelClopidogrel Bisulfate | 246 | $2,800 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 226 | $2,610 |
| Atorvastatin Calcium | 163 | $2,398 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 36 | $2,151 |
| Flecainide Acetate | 36 | $1,555 |
| Nitroglycerin | 72 | $1,474 |
| Rosuvastatin Calcium | 111 | $1,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $181 | $295,732378 claims |
| NovartisEntresto | $485 | $53,13957 claims |
| Johnson & JohnsonXarelto | $253 | $41,11046 claims |
| AstraZenecaBrilinta, Farxiga | $199 | $37,01764 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Kingsport
- Rahul SakhujaKingsport$46K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Ayaz RahmanKnoxville$251K
- Samuel HorrNashville$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.